215 related articles for article (PubMed ID: 21537872)
21. Role of
Sasaki K; Uchikado Y; Okumura H; Omoto I; Kita Y; Arigami T; Uenosono Y; Owaki T; Maemura K; Natsugoe S
Anticancer Res; 2017 Feb; 37(2):859-864. PubMed ID: 28179343
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.
Yap WK; Chang YC; Tseng CK; Hsieh CH; Chao YK; Su PJ; Hou MM; Yang CK; Pai PC; Lin CR; Hsieh CE; Wu YY; Hung TM
Dis Esophagus; 2017 Aug; 30(8):1-10. PubMed ID: 28575243
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
[TBL] [Abstract][Full Text] [Related]
24. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer.
Ott K; Herrmann K; Schuster T; Langer R; Becker K; Wieder HA; Wester HJ; Siewert JR; zum Büschenfelde CM; Buck AK; Wilhelm D; Ebert MP; Peschel C; Schwaiger M; Lordick F; Krause BJ
Ann Surg Oncol; 2011 Nov; 18(12):3316-23. PubMed ID: 21537865
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis.
Pan L; Gu P; Huang G; Xue H; Wu S
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1008-15. PubMed ID: 19352191
[TBL] [Abstract][Full Text] [Related]
26. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
[TBL] [Abstract][Full Text] [Related]
27. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
[TBL] [Abstract][Full Text] [Related]
28. Comparison of uptake characteristics and prognostic value of 201Tl and 18F-FDG in esophageal cancer.
Chung HW; Lee KH; Lee EJ; Lee SJ; Cho YS; Choi JY; Shim YM; Kim K; Kim BT
World J Surg; 2008 Jan; 32(1):69-75. PubMed ID: 17985103
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging
Beukinga RJ; Hulshoff JB; Mul VEM; Noordzij W; Kats-Ugurlu G; Slart RHJA; Plukker JTM
Radiology; 2018 Jun; 287(3):983-992. PubMed ID: 29533721
[TBL] [Abstract][Full Text] [Related]
30. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
Stiekema J; Vermeulen D; Vegt E; Voncken FE; Aleman BM; Sanders J; Boot H; van Sandick JW
Clin Nucl Med; 2014 Oct; 39(10):862-7. PubMed ID: 25140549
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of ¹⁸F-fluorodeoxyglucose positron emission tomography in superficial esophageal squamous cell carcinoma.
Kita Y; Okumura H; Uchikado Y; Sasaki K; Omoto I; Matsumoto M; Setoyama T; Tanoue K; Mori S; Owaki T; Ishigami S; Ueno S; Kajiya Y; Natsugoe S
Ann Surg Oncol; 2013 May; 20(5):1646-52. PubMed ID: 23238695
[TBL] [Abstract][Full Text] [Related]
32. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications.
Choi JY; Jang HJ; Shim YM; Kim K; Lee KS; Lee KH; Choi Y; Choe YS; Kim BT
J Nucl Med; 2004 Nov; 45(11):1843-50. PubMed ID: 15534053
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
Song SY; Kim JH; Ryu JS; Lee GH; Kim SB; Park SI; Song HY; Cho KJ; Ahn SD; Lee SW; Shin SS; Choi EK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1053-9. PubMed ID: 15964705
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma.
Toriyama K; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Onishi S; Mizuno N; Kuwahara T; Okuno N; Matsumoto S; Sasaki E; Abe T; Yatabe Y; Hara K; Matsuo K; Tamaki T; Niwa Y
World J Gastroenterol; 2019 Dec; 25(46):6767-6780. PubMed ID: 31857778
[TBL] [Abstract][Full Text] [Related]
36. 18F-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer: systematic review of the literature.
Rebollo Aguirre AC; Ramos-Font C; Villegas Portero R; Cook GJ; Llamas Elvira JM; Tabares AR
Ann Surg; 2009 Aug; 250(2):247-54. PubMed ID: 19638908
[TBL] [Abstract][Full Text] [Related]
37. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Jones DR
Eur J Cardiothorac Surg; 2009 Apr; 35(4):699-705. PubMed ID: 19136271
[TBL] [Abstract][Full Text] [Related]
38. Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.
Hatt M; Le Pogam A; Visvikis D; Pradier O; Cheze Le Rest C
J Nucl Med; 2012 Jan; 53(1):12-20. PubMed ID: 22213819
[TBL] [Abstract][Full Text] [Related]
39. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
[TBL] [Abstract][Full Text] [Related]
40. The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma.
Klayton T; Li T; Yu JQ; Keller L; Cheng J; Cohen SJ; Meropol NJ; Scott W; Xu-Welliver M; Konski A
J Gastrointest Cancer; 2012 Dec; 43(4):612-8. PubMed ID: 22777832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
